NCT06943755Phase 2, phase 3Recruiting

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Study sponsor: Exelixis

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2029-06-30Estimated

Enrollment · participants440Estimated

Source updated2026-09-10Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-09 · 1 field changed

Primary completion date

Recorded edit

− Previous value

2029-06

+ Updated value

2029-06-30

Check registry source